Clinical observation of 40 patients with malignant lymphoma treated with high dose chemotherapy combined with autologous hematopoietic stem cell transplantation

doi:10.12092/j.issn.1009-2501.2018.12.014

Abstract

Abstract:

AIM: To investigate the therapeutic effect of the patients with malignant lymphoma treated with high dose chemotherapy combined with autologous hematopoietic stem cell transplantation (AHSCT)．METHODS: The follow up data in 40 patients with malignant lymphoma who recieved AHSCT in Anhui Province Cancer Hospital from March 2013 to February 2018 were analyzed retrospectively．Of the 40 patients, 4 were Hodgkin's lymphoma (HL) and 36 were non-Hodgkin's lymphoma (NHL). To mobilize peripheral hematopoietic stem cell, etoposide combined with G-CSF was used. Preconditioning regimens included BEAM, CBV and BEAC. RESULTS:All patients were collected enough peripheral blood stem cells．None of the patients were died for the risks of AHSCT. The median time of the absolute neutrophil count (ANC) implanted was 10 (7-17) days．And the median time of platelet count implanted was 12 (6-25) days．The median survival time was 15 (1-53) months, progression free survival (PFS) was 72.5%，and overall survival (OS) was 82.5%.The patients who achieved CR status before transplantation could have a favorable prognosis. The prognosis in the patients with IPI score>2 was poor.CONCLUSION:AHSCT can improve the prognosis of patients with malignat lymphoma.

Key words: lymphoma, autologous hematopoietic stem cell transplantation, hematopoietic stem cell transplantation

CLC Number:

R733
R552

FENG Yuanyuan, DING Kaiyang, WANG Cuicui. Clinical observation of 40 patients with malignant lymphoma treated with high dose chemotherapy combined with autologous hematopoietic stem cell transplantation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1397-1401.

References

［1］Stiff PJ,Unger JM,Cook JR,et al.Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma［J］.N Engl J Med,2013,369(18):1681-1690．
［2］Nagle SJ,Woo K,Schuster SJ,et al.Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era［J］.Am J Hematol,2013,88(10):890-894.
［3］赵瑾,苏丽萍,王晶荣,等.自体造血干细胞移植治疗恶性淋巴瘤效果观察［J］.淋巴瘤·白血病,2015,24(11):679-681.
［4］Grawohl A, Hermans J, Baldomero H. Blood and marraw transplantation activity in Europe 1995［J］. Bone Marrow Transplant, 1997, 19:407-419.
［5］Philip T,Guglielmi C,Hagenbeek A,et al.Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma［J］.N Engl J Med,1995,333(23):1540-1545.
［6］Czyz A,Lojko-Dankowska A,Dytfeld D,et al.Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma:a single-center experience［J］.Med Oncol,2013,30(3):611.
［7］马军，邱录贵．应重视造血干细胞移植在淋巴瘤治疗中的应用与推广［J］.中华血液学杂志,2014,35(4):273-274．
［8］Zelenetz Ad,Gordon LI,Wierda WG,et al.Non-Hodgkin's lymphomas,version 2.2014［J］.J Natl Compr Canc Netw,2014,12(6):916-946.
［9］Yin J，Wei J, Xu JH, et al.Autologous stem cell transplantation asthe first-line treatment for peripheral T cell lymphoma:results of a comprehensive meta-analysis［J］.Acta Haematol,2014,131（2）:114-125.
［10］Yoon JH, Kim JW, Jeon YW, et al. Role of frontline autologous stem cell transplantation in young,high-risk diffuse large B-cell lymphoma patients［J］.Korean J Intern Med, 2015, 30（3）:362-371.
［11］Smith SD, Bolwell BJ, Rybicki LA, et al. Comparison of outcomes after auto-SCT for patients with relapsed diffuse largeB-cell lmphoma according to previous therapy with rituximab［J］.Bone Marrow Transplant,2011,46(2):262-266.
［12］Williams ME,Densmore JJ.Biology and therapy of mantle cell lymphoma［J］.Curr Opin Oncol,2005,17(5):425-431.
［13］Lacasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database［J］.Blood,2012,119(9):2093-2099.
［14］Gui L, Shi YK, He XH, et a1.High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis［J］. Int J Hematol,2014,99(1):69-78．
［15］Shin HJ, Lee WS, Lee HS, et al.Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma［J］.Leuk Lymphoma,2014,55(11):2490-2496．
［16］William BM, Loberiza FR, Whalen V, et al. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma［J］.Clin Lymphoma Myeloma Leuk,2013,13(4):417-423．
［17］蒲欣,陈洁平.自体造血干细胞移植治疗高危难治淋巴瘤生存分析［J］.重庆医学，2016，45(12)：1620-1623.
［18］王莉,范磊，徐卫，等.自体造血干细胞移植治疗81例恶性淋巴瘤患者临床分析［J］．中华血液学杂志，2014，35(4)：328-331．

[1]	WANG Tiantian, CAO Junjie, LIU Xuhui, PEI Renzhi, LU Ying. Clinical analysis of the effect of fludarabine combined with post-transplantation cyclophosphamide in haploid hematopoietic stem cell transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 295-301.
[2]	LI Wenxia, FANG Liuyuan, QIAN Shenxian. Mechanism of ferroptosis and its research progress in lymphoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 314-321.
[3]	PENG Min, HUANG Panhao, DENG Yinhua, LIU Wen, LI Wei, YU Zhen, XIA Qing, XIE Yueliang. Analysis of influence factors of voriconazole trough concentration in patients with hematopoietic stem cell transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 640-646.
[4]	LOU Anqi, YU Junxian, CHENG Zizhao, SU Qiang. Bruton tyrosine kinase inhibitors and refractory mantle cell lymphoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 680-686.
[5]	PAN Zhanhe, WANG Xin, SU An, ZHANG Peng, JI Haonan, WANG Xiaomei. Mechanism of celecoxib reverses adriamycin resistance in NK/T cell lymphoma cells by Notch 1/NF-κB/STAT3 pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1330-1336.
[6]	CHANG Xiangxiang, WEI Zhongling, ZHENG Xingyuan, LI Huimin, HUANG Laiquan. Progress in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 107-116.
[7]	CHEN Bing, ZHANG Fan, LU Lin-ming, ZHU Xiao-qun, LIU Yin-hua, He Lei. Analysis distribution of 728 cases with malignant lymphoma by wannan area of China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 388-393.
[8]	SHENG Li-li, LIU Yin-hua, JI Zhao-ning. Expression and significance of PTEN and LIVIN in diffuse large B-cell lymphoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(4): 376-380.
[9]	CHEN Jun-fa, ZHENG Zhi-yin, SHEN Jian-ping, ZHOU Yu-hong. Effects of hemopoietic stem cell mobilized by Hyper-CVAD/MA+G-CSF on lymphoma patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1410-1413.
[10]	JI Zhao-Ning, LIU Guo-Qing, XU Dou-Rong, HONG Wen-De. Detection of homozygous P16 gene deletion in Non-Hodgkin' s Lymphoma by semiquantitative multiplex polymerase reaction and it' s clinical signifi-cance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(1): 60-62.